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Abstract
Background: In this study, we investigated whether the infusion of bone marrow-derived mesenchymal stem cells (MSCs),
combined with transient immunosuppressant treatment, could suppress allograft rejection and modulate T-cell regulation
in a swine orthotopic hemi-facial composite tissue allotransplantation (CTA) model.
Methodology/Principal Findings: Outbred miniature swine underwent hemi-facial allotransplantation (day 0). Group-I
(n=5) consisted of untreated control animals. Group-II (n=3) animals received MSCs alone (given on days 21, +1, +3, +7,
+14, and +21). Group-III (n=3) animals received CsA (days 0 to +28). Group-IV (n=5) animals received CsA (days 0 to +28)
and MSCs (days 21, +1, +3, +7, +14, and +21). The transplanted face tissue was observed daily for signs of rejection. Biopsies
of donor tissues and recipient blood sample were obtained at specified predetermined times (per 2 weeks post-transplant)
or at the time of clinically evident rejection. Our results indicated that the MSC-CsA group had significantly prolonged
allograft survival compared to the other groups (P,0.001). Histological examination of the MSC-CsA group displayed the
lowest degree of rejection in alloskin and lymphoid gland tissues. TNF-a expression in circulating blood revealed significant
suppression in the MSC and MSC-CsA treatment groups, as compared to that in controls. IHC staining showed CD45 and IL-
6 expression were significantly decreased in MSC-CsA treatment groups compared to controls. The number of CD4+/CD25+
regulatory T-cells and IL-10 expressions in the circulating blood significantly increased in the MSC-CsA group compared to
the other groups. IHC staining of alloskin tissue biopsies revealed a significant increase in the numbers of foxp3
+T-cells and
TGF-b1 positive cells in the MSC-CsA group compared to the other groups.
Conclusions: These results demonstrate that MSCs significantly prolong hemifacial CTA survival. Our data indicate the MSCs
did not only suppress inflammation and acute rejection of CTA, but also modulate T-cell regulation and related cytokines
expression.
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Introduction
Mesenchymal stem cells (MSCs) from the bone marrow are
multi-potential non-hematopoietic progenitor cells in the adult
marrow capable of differentiating into various mesenchymal cell
types. Previous studies have revealed that MSCs do not express
immunogenic co-stimulatory molecules, such as B7-1, B7-2, or
CD40 [1–2]. Therefore, it is likely that they are unable to
stimulate alloreactive T-cells. The immunomodulatory effects of
MSCs have been demonstrated both in vitro and in vivo [3]. Studies
have indicated that donor MSCs are potent inhibitors of T-cell
proliferation in mixed lymphocyte cultures, thus preventing graft-
versus-host disease (GVHD) caused by bone marrow transplan-
tation (BMT) and prolonging skin allograft survival in rodent
models [4].
In a previous study, we clearly showed that donor bone
marrow-derived MSC therapy, in addition to BMT, after total
body irradiation and short-term cyclosporine A (CsA) treatment
significantly improved allotransplant survival without signs of
GVHD in a swine heterotopic hind-limb composite tissue
allotransplantation (CTA) model [5]. We further demonstrated
that the administration of multiple donor MSCs without BMT has
similar results on allotransplant survival in the same model [6].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35459Our results led us to speculate that BMT is unnecessary to prolong
CTA survival if MSCs are used as an immunosuppressant [5]. The
miniature swine hemi-facial CTA model (consisting of skin paddle,
muscle, ear cartilage, and lymphoid gland tissue) had been
established by our institute recently [7]. The difference between
the hemifacial CTA model and the hind-limb model is that this
hemi-facial model does not contain donor vascularized bone, but it
does include more alloskin area and lymphoid gland tissue.
However, there have not been any studies that have assessed the
effects of MSCs in a large animal facial allotransplant study. To re-
confirm this hypothesis and to test another CTA model for pre-
clinical study, we designed the current protocol to investigate
whether multiple treatments with MSCs combined with treatment
with a transient immunosuppressant yielded reproducible results
and prolonged allotransplant survival in a miniature swine hemi-
facial model (Fig. 1). We also examined how the immunoregula-
tory effects of MSCs could contribute to prolonged CTA survival.
Results
MSC therapy combined with transient
immunosuppressant treatment prolongs hemi-facial
allotransplant survival
Allograft recipients treated with multiple short-term MSC
injections in the absence of immunosuppressant treatment (group
II) revealed a trend but no statistically significant increase in
allograft survival 17–38 days post-transplantation compared to the
controls, which survived for 7–28 days (p=0.123). Allotransplan-
tation, along with short-term CsA treatment, for 4 weeks in group
III resulted in delayed rejection compared to that of controls
(p=0.018). However, treatment with MSCs in addition to
transient CsA treatment (group IV) resulted in significant increases
in allograft survival when compared to other experimental groups
(Fig. 2, p,0.05).
MSC therapy with short-term immunosuppressant
treatment suppresses hemi-facial allotransplant rejection
Histopathological evaluation revealed severe graft acute rejec-
tion (grade III), including inflammatory cell infiltrates in grafted
skin and in lymphoid gland samples of untreated controls at 2
weeks post-transplantation. Allograft biopsies from animals treated
with MSCs alone revealed moderate to severe rejection (grades II–
III) in the grafted skin in the dermal-epidermal junction,
subcutaneous tissue, and gland tissue at 2 weeks post-transplan-
tation. CsA-treated animals revealed grade I rejection in the
alloskin and gland tissue at 2 weeks post-transplant, while there
was mild to moderate lymphocyte infiltration in the gland tissue
and alloskin (grade II–III) at 6 weeks post-transplantation.
However, the MSC-CsA group revealed mild lymphocyte
infiltration in the grafted skin (grade I) or lymphoid gland tissue
(grade I) when compared to other groups at 2 weeks and 6 weeks
post-transplantation (Fig. 3). This indicated MSCs could modulate
early allograft acute rejection.
MSC therapy increased regulatory T-cell populations in
the peripheral blood and allotransplant tissues
Flow cytometric analysis of recipient peripheral blood revealed
that the proportion of CD4+/CD25+ T-cells increased signifi-
cantly in animals treated with MSCs-CsA at 2 weeks post-
transplantation compared to controls (Fig. 4A). The CD4+/
foxp3+ expressions in circulating blood have a tendency to
increase in MSC-CsA group as compared with those in the other
groups (Fig. 4B). These indicated MSC and CsA regulate T-cells
expression in the early stage post-transplant. In contrast, IHC
staining of alloskin tissue biopsies revealed a significant increase in
the numbers of CD25+ and foxp3+ T-cells in the subcutaneous
and dermis layers of animals treated with MSCs-CsA compared to
the other groups at 2 weeks post-transplantation (Fig. 5A and
Fig. 5B). The CD25+ T cells were expressed on similar site of
foxp3+ cells. The levels of CD25+ and foxp3+ T-cells in the MSC-
CsA group were still higher at 6 weeks post-transplantation
compared to other groups.
MSC and transient immunosuppressive therapy
regulated the pro-inflammatory and anti-inflammatory
cytokines
The concentrations of the soluble forms of TNF-a, IL-10, and
TGF-bl were determined by ELISA after the various treatments.
Analysis of recipient peripheral blood serum revealed the TNF-a
level had a significant decrease in animals treated with MSCs and
Figure 1. The flowchart of the timetable of this study is shown. Outbred miniature swine underwent hemi-facial allotransplantation (day 0).
Group I consisted of the control cohort that did not undergo immunosuppressive therapy. Group II received MSCs alone (2.5610
7 MSCs/dose, given
on days 21, +1, +3, +7, +14, and +21). Group III received cyclosporine A (CsA) for 4 weeks (days 0 to +28; 10 mg/kg for 2 weeks, followed by 5 mg/kg
for 2 weeks). Group IV received CsA (days 0 to +28) and MSCs (given on days 21, +1, +3, +7, +14, and +21).
doi:10.1371/journal.pone.0035459.g001
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those in controls (Fig. 6A). The IL-10 level had a statistically
significant increase in animals treated with MSC and MSC-CsA
groups at 2 weeks post-transplantation, as compared to controls
(Fig. 6B). In contrast, TGF-bl levels of recipient peripheral blood
serum showed a trend of increase but no significant difference
between MSC groups and the controls.
The IHC staining of alloskin biopsy revealed significantly lower
numbers of CD45 and IL-6 positive cells in the subcutaneous and
dermis layers of skin from animals treated with MSC and MSC-
CsA groups, compared to the controls (Fig. 7A and 7B). The
alloskin biopsy revealed significantly increased the numbers of
TGF-bl positive cells in the subcutaneous and dermis layers of skin
from animals treated with MSC at 2 weeks post-transplantation
and MSC-CsA groups at 2 and 6 weeks post-transplantation
compared to controls (Fig. 7C).
Discussion
Composite tissue allotransplantations are not routinely per-
formed for tissue reconstruction because of the potentially harmful
adverse effects associated with lifelong administration of immu-
nosuppressive agents, which is required for highly antigenic tissue.
Therefore, the development of novel and non-toxic strategies that
circumvent the long-term use of immunosuppressants is critical.
Recently, the immunoregulatory properties of MSCs were
described. Studies indicated MSC infusion had good effects on
many immuno-diseases [3,8–10]. Our previous study revealed that
the infusion of donor bone marrow-derived MSCs could prolong
allotransplant survival; in addition, we showed that the presence of
MSCs correlated with increases in regulatory T-cell populations in
a swine heterotopic hind-limb model (consisting of skin, muscle,
knee joint, vascularized bone and bone marrow) [9–11]. In the
present study, we investigated whether multiple treatments with
MSCs combined with a transient immunosuppressant could
reproduce the increase in allograft survival using a miniature
swine hemi-facial allotransplant model. However, the different
animal models of CTA may cause the different outcome by MSC
infusion. Our present study showed that MSCs alone without
short-term CsA had just a tendency to prolong the survival but not
statistically prolonged swine hemifacial CTA survival. These
discrepancies may be explained by the difference of the amount of
alloskin between swine hemifacial transplant model and other
CTA models. Especially, swine hemifacial CTA model owns more
alloskin and lymphoid gland tissue without donor vascularized
bone marrow. As far as we know, allo-skin is the highest
antigenicity to induce immune rejection. Skin transplantation
with donor bone marrow might provide more stem cells to
modulate recipient T-cell regulation.
In contrast, the recipients treated with short-term CsA were
characterized by a significant increase in allotransplant survival
compared to the untreated controls. Interestingly, the recipients
treated with MSCs combined with a transient CsA regimen
displayed more significant prolongation of allograft survival than
the CsA alone group, although the allograft was eventually
rejected. Although animal number in each group may not be
Figure 2. Treatment with MSCs and transient immunosuppressive therapy prolongs hemi-facial allotransplant survival. Multiple MSC
injections in the absence of immunosuppression (group II) produced a trend but not a statistically significant increase in allotransplant survival
compared to controls. Allotransplants in group III animals, which received short-term CsA treatment, displayed delayed rejection and survival for 36–
48 days post-transplant (p=0.018). The combination of MSC injections with CsA treatment (group IV) significantly prolonged allotransplant survival
compared to other groups (p,0.001). One swine was sacrificed (day 38 post-transplantation) due to severe infection, although the allotransplant was
still viable. Another died incidentally during biopsy (day 71 post-transplantation).
doi:10.1371/journal.pone.0035459.g002
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enough for statistical analysis [6]. Results indicated the MSC/CsA
group statistically prolonged allotransplant survival as compared to
that in controls. Multiple MSC infusions in combination with
conventional CsA treatment would indeed constitute a novel
strategy to substantially prolong hemi-facial composite tissue
allotransplant survival. Therefore, adjustment of the dosage or
the timing of MSCs infusion in hemi-facial CTA are still needed to
assess the function of MSCs.
Allogeneic skin and lymphoid gland tissue are considered to be
the most antigenic tissue involved in hemi-facial CTA procedures
[11–12]. In our hemi-facial model, histopathological analysis of
untreated controls revealed substantial, severe acute rejection in
alloskin and lymphoid gland tissue (grade III) 2 weeks post-
transplantation. Although the MSCs alone group did not display a
statistically significant prolongation of allotransplant survival,
donor skin and lymphoid gland biopsies revealed less rejection
signs (grade II–III) than controls 2 weeks post-transplantation.
This indicates that the MSCs, at least in part, suppress allograft
rejection. The recipients that received a therapy that combined
MSC infusions with short-term CsA treatment did not demon-
strate apparent signs of rejection in either grafted skin or lymphoid
gland biopsies at 6 weeks post-transplantation. In contrast, the
TNF-a level determined by ELISA revealed a significant decrease
in animals treated with MSCs and MSC/CsA groups at 2 weeks
post-transplantation compared to controls. The IHC staining of
alloskin biopsy revealed significantly lower numbers of CD45 and
IL-6 positive cells in the subcutaneous and dermis layers of skin
from animals treated with MSC and MSC/CsA groups, as
compared to those in controls. These results indicate that multiple
MSC infusions combined with short-term immunosuppressant
therapy could prevent acute rejection and prolong CTA survival.
Recently, the immunomodulatory properties of MSC infusions
have been described. Studies indicated that MSCs modulate
immune responses through the induction of regulatory T-cells
[2,13–15]. Additional studies have suggested that MSCs may
inhibit T-cell activation, thereby prolonging skin graft survival in a
rodent model [8]. Studies indicated MSCs have immuno-
modulatory properties and involve regulatory T-cells while
cyclosporine did not increase the percentage of CD4+/CD25+/
foxp3+ T-cells in a rat cardiac allograft [16–17]. In this study,
single MSCs or CsA alone did not have a significant effect to affect
the percentage of CD4+/CD25+ and CD4+/foxp3+ regulatory T-
cells. However, FACS analysis of the CD4+/CD25+ and CD4+/
foxp3+ regulatory T-cell populations in recipient peripheral blood
revealed significantly expanded regulatory T-cell populations in
animals treated with MSCs and CsA compared to controls at 2
weeks post-transplantation. Immunohistochemical staining of
allograft tissue showed significant increases in CD25+ and Foxp3+
T-cell populations in the subcutaneous and dermis layers of the
skin. The reason should be the synergistic effect of MSC injections
and CsA administration increase allotransplant survival and
Figure 3. Histopathological examination of MSCs and short-term cyclosporine A (CsA) decreases allotransplant rejection.
Histopathological evaluation revealed signs of severe rejection (grade III) including diffuse, dense polymorphic inflammatory cells infiltrate beneath
the dermal-epidermal junction in grafted skin and lymphoid gland tissues of untreated controls at 2 weeks post-transplantation (arrow). Animals in
the MSC alone group showed moderate rejection (grade II) with a slighted dense dermal infiltrate inflammatory cells around dermal blood vessels
and diffusing interstitially in lymphoid gland tissues at 2 weeks post-transplantation. Animals in the CsA group showed a dense perivascular dermal
lymphocytic infiltrate, extending focally into the epidermis (grade II–III) at 6 weeks post-transplantation. Animals in the MSC-CsA group revealed small
number perivascular lymphocytes infiltrated in the alloskin (grade I) or lymphoid gland tissue (grade I) when compared to other groups at 6 weeks
post-transplantation. Photo magnification is 1006in skin and lymphoid gland tissue. Scale bar=10 mm.
doi:10.1371/journal.pone.0035459.g003
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concentrations of IL-10 in recipient peripheral blood serum
revealed statistical increase in animals treated with MSC and
MSC-CsA groups at 2 weeks post-transplantation compared to
controls. The IHC staining of alloskin biopsy revealed significantly
lower numbers of TGF-bl positive cells in the subcutaneous and
dermis layers of skin from animals treated with MSC and MSC/
CsA groups at 6 weeks post-transplantation compared to controls.
This demonstrated the possible mechanism of MSC and CsA
Figure 4. Treatment with MSCs and short-term CsA increases regulatory T-cell populations in recipient peripheral blood samples.
Flow cytometry analysis indicated that CD4+/CD25+ regulatory T-cell populations were significantly increased in animals treated with MSCs and CsA
compared to controls (Fig. 4A, *P=0.015). In contrast, flow cytometry analysis indicated that CD4+/foxp3+ regulatory T-cell populations were a
trend increased in animals treated with MSCs and CsA compared to controls (Fig. 4B).
doi:10.1371/journal.pone.0035459.g004
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and induced a more anti-inflammatory effect.
In summary, this pre-clinical study indicates that multiple
infusions of donor MSCs combined with transient immunosup-
pressant treatment can effectively prolong allotransplant survival
in a swine hemi-facial allotransplant model. This large animal
CTA model reconfirms the hypothesis that MSCs have immuno-
modulatory effects mediated by the suppression of allograft
Figure 5. Treatment with MSCs and a transient immunosuppressant increased CD25+ and Foxp3+ T-cell populations in
transplanted alloskin tissues. IHC staining of biopsy tissue in donor skin from the MSC-CsA group revealed significantly increased numbers of
CD25+ T-cells in the subcutaneous and dermis layers compared to the control group (Fig. 5A,* P,0.05). The MSC-CsA group revealed significantly
increased numbers of foxp3+ T-cells in the subcutaneous and dermis layers compared to control groups 2 weeks post-transplantation (Fig. 5B,
*P,0.05). Photo magnification is 4006. Scale bar=50 mm.
doi:10.1371/journal.pone.0035459.g005
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infusion is a novel strategy for increasing CTA survival.
Materials and Methods
Animals
Twenty-four outbred domestic miniature swine (Lan-Yu strain
and Hwa-Ban strain; age, 3 months; weight, 12–20 kg) were
included in this study. The miniature swine is an indigenous breed
from Lau-Yu Islet, southeast of Taiwan. This study was conducted
Figure 6. MSC and transient immunosuppressive therapy regulated the pro-inflammatory and anti-inflammatory cytokines. The
concentrations of the soluble forms of TNF-a determined by ELISA revealed a significant decrease in animals treated with MSCs and MSC-CsA groups
at 2 weeks post-transplantation compared to controls (Fig. 6A, *P,0.05). The concentrations of the soluble forms of IL-10 revealed that IL-10 level
was statistically increased in animals treated with MSC and MSC-CsA groups at 2 weeks post-transplantation compared to controls (Fig. 6B,*
P,0.01).
doi:10.1371/journal.pone.0035459.g006
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subcutaneous and dermis layers of skin from animals treated with MSC and MSC-CsA groups, compared to the controls (Fig. 7A
and 7B, *P,0.05). The IHC staining of alloskin biopsy revealed significantly increased the numbers of TGF-bl positive cells in the subcutaneous and
dermis layers of skin from animals treated with MSC and MSC-CsA groups at 6 weeks post-transplantation compared to controls (Fig. 7C * P,0.05).
Scale bar=50 mm.
doi:10.1371/journal.pone.0035459.g007
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Animals published by the National Institutes of Health, U.S.A.
Experiments were conducted using the Institutional Animal Care
and Use Committee (IACUC) protocol approved by the
Kaohsiung Chang Gung Memorial Hospital, Taiwan.
Hemi-facial composite tissue allotransplant swine model
Orthotopic hemi-facial allotransplantation (Hwa-Ban strain to
Lan-Yu strain) was performed as described previously [7]. The
swine hemi-facial transplantation tissue consisted of ear cartilage,
auricular nerve, parotid gland, lymphoid tissue, and muscle with
surrounding hemi-facial skin paddle [7]. The vascular territories of
the composite allotransplant supplied by the superficial temporal
artery and its branches originating from the carotid artery were
defined. The common carotid artery and external jugular vein were
dissected as the vascular pedicle of the allotransplant. After flushed
heparinized-saline solution, the hemi-facial flap was secured and
sutured in the recipient. End to end venous anastomosis was
performed between the external jugular vein of the donor and
recipient. Then, end-to-side anastomosis between the common
carotid artery of the recipient and donor was performed under
operating microscope magnification.
Experimental design
Miniatureswineunderwentorthotopichemi-facialallotransplan-
tation. Group I (n=5) was the control cohort, and the animals did
not undergo immunosuppressive therapy. Group II (n=3) animals
received MSCs alone (2.5610
7 MSCs/dose, given on days 21, +1,
+3, +7, +14, and +21). Group III (n=3) animals received
cyclosporine A (CsA) for 4 weeks (days 0 to +28; 10 mg/kg for 2
weeks, followed by 5 mg/kg for 2 weeks). Group IV (n=5) animals
received CsA (same protocol as group III; days 0 to +28) and MSCs
(2.5610
7MSCs/dose, givenondays 21,+1,+3,+7,+14,and +21).
The flowchart of the timetable in this study is shown in Fig. 1. This
work was supported in part by Chang Gung Research Project
(Contract No. grant CMRPG-850081 and CMRPG-860452).
Swine viability and signs of allograft rejection were continuously
monitored postoperatively. The clinical experimental endpoint was
defined as desquamation and necrosis of the entire area of donor
skin.
Culturing of MSCs
Bone marrow cells from donors were harvested and isolated 2
weekspriortoCTAusingmethodsdescribedpreviously[5].Briefly,
bone marrow cells were suspended in low-glucose Dulbecco’s
Minimal Essential Medium (DMEM), 10% fetal bovine serum
(FBS), antibiotic/antimycotic, and glutamax, and the cells were
platedin6-welldishes.Thecultureswereincubatedat37uCina5%
CO2 atmosphere. After 4 hrs of subtraction and removal of
adherent cells, the non-adherent cells were transferred to 25-T
subcultureflasks.Whentheywere70–80%confluent,adherentcells
were trypsinized (0.05% trypsin at 37uC for 5 min), harvested, and
expanded into 75-T flasks. MSCs were expanded in culture and
demonstratedpositivesurfacestainingforCD44,CD90,MHCclass
I,andCD106butnotforCD45,MHCclassII,and CD80/B7-1,as
revealedbyflowcytometry [5].MSCsweretestedfor theirabilityto
differentiate into adipocytes, osteoblasts, and chondrocytes before
use [5].
Histological evaluation of graft rejection
Biopsies of donor skin, gland lymphoid tissue and cartilage were
obtained atspecifiedpredeterminedtimesoratthetimeofclinically
evident rejection [7,18]. According to the severity of pathological
changes, rejection grades using the Banff classification were applied
[19].
Flow cytometric assessment of T-cell regulation
Flow cytometric analysis was performed on peripheral blood
samples of recipients collected on specified days post-transplant.
Blood sample was incubated in the dark (room temperature) with
mouse anti-porcine CD25-fluorescein isothiocyanate (FITC) (Phar-
migen,USA)andmouseanti-pigCD4-phycoerythrin(PE).Another
sample was stained with a combination of FITC-conjugated mouse
anti-rat Forkhead box P3 (foxp3) antibody (eBioscience) and CD4-
labeled PE. After incubation, red blood cells were lysed, and the
remaining cells were centrifuged. The cells were then analyzed by
flow cytometry (FACScan, Becton Dickinson)
Cytokine detection of TNF-a, IL-10, and TGF-b1
The soluble forms of tumor necrosis factor-alpha (TNF-a),
interleukin-10 (IL-10), and transforming growth factor-bl (TGF-bl)
were determined by an enzyme-linked immunosorbent assay
(ELISA) kit (R&D system, Minneapolis, MN). Blood serum samples
were collected at predetermined specific days post-transplantation.
Immunohistochemical (IHC) staining
Tissue sections were subjected to IHC for CD25, foxp3, and
TGF-b1 to investigate T-cell regulation, CD45 and IL-6 for pro-
inflammatory reaction. A horseradish peroxidase-diaminobenzi-
dine(HRP–DAB)kitwasused(BioGeneX,USA).Afterendogenous
peroxidase activity was blocked with 3% hydrogen peroxide, tissue
sectionswerestained withmouseanti-porcine CD25(Serotec, UK),
anti-foxp3 (Serotec, UK), anti-TGF-b1 (Abcam, UK), and anti-
CD45 antibody (Serotec, UK). The reaction sections were
incubated with a biotinylated anti-mouse antibody as a secondary
antibody. Visualization of specific binding was developed by
enzymatic conversion of the chromogenic substrate 3, 39-DAB into
a brown precipitate by HRP. After counterstaining with hematox-
ylin, donor tissue sections were mounted, cleared, and coverslipped
[20].
Histomorphometric analysis
For immunostaining quantification, the tissue sections were
analyzed using a Zeiss Axioskop 2 Plus microscope (Carl Zeiss,
Gottingen, Germany). Four randomly selected areas were then
photographed at 4006 magnification. All images were captured
using a Cool CCD camera. The images were analyzed using the
Image-Pro Plus image analysis software (Media Cybernetics,
Silverbernetics Spring, MD) [20].
Statistical analyses
Student’s t-test or ANOVA was utilized to assess the statistical
significance of differences among experimental groups. Log
transformation prior to variance analysis and Student’s t-test was
performed to reconfirm normality and equal variances for flow
cytometry data. Graft survival was compared among the different
groupsoftransplantedanimalsusingKaplan-Meieranalysisandthe
log-rank test. A P value of less than 0.05 was considered statistically
significant.
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